TY - JOUR
T1 - Pharmacokinetics of mizoribine in adult living donor liver transplantation
AU - Shinoda, Masahiro
AU - Tanabe, M.
AU - Kawachi, S.
AU - Ono, Y.
AU - Hayakawa, Tomohisa
AU - Iketani, O.
AU - Kojima, M.
AU - Itano, Osamu
AU - Obara, H.
AU - Kitago, M.
AU - Hibi, Taizo
AU - Matsubara, K.
AU - Shimojima, Naoki
AU - Fuchimoto, Yasushi
AU - Hoshino, Ken
AU - Wakabayashi, G.
AU - Shimazu, M.
AU - Tanigawara, Yusuke
AU - Kuroda, T.
AU - Morikawa, Y.
AU - Kitajima, M.
AU - Kitagawa, Y.
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/6
Y1 - 2012/6
N2 - We investigated the pharmacokinetics of mizoribine in the acute phase after adult living donor liver transplantation (LDLT). Between February 2004 and October 2009, 16 recipients received immunosuppressive therapy that included mizoribine (100 to 200 mg/d) after undergoing LDLT. We determined the serum levels of mizoribine before (C0) and 3 (C3), 4 (C4), and 10 (C10) hours after administration on postoperative days 3, 7, and 21. We assessed area under the concentration time curve (AUC) (hour · μg/mL), normalized serum concentration (NSC) at C0 [concentration (μg/mL)/dose (mg/kg body weight)], and estimated glomerular filtration rate (eGFR). The mizoribine concentration showed increases at C3 and C4 followed by a decrease at C10 on all days. AUC was 4.3, 5.9, and 8.3 in the 200-mg/d dose group on days 3, 7, and 21, respectively. NSC at C0 increased for 3 weeks after LDLT. There was a significant correlation between the NSC at C0 and eGFR on day 21, but not on days 3 and 7. There were no correlations between the NSC at C0 and either aspartate aminotransferase, total bilirubin, albumin, trough cyclosporine, or trough tacrolimus on any day. The pharmacokinetics of mizoribine in the acute phase after LDLT seems to be affected by postoperative day and renal function.
AB - We investigated the pharmacokinetics of mizoribine in the acute phase after adult living donor liver transplantation (LDLT). Between February 2004 and October 2009, 16 recipients received immunosuppressive therapy that included mizoribine (100 to 200 mg/d) after undergoing LDLT. We determined the serum levels of mizoribine before (C0) and 3 (C3), 4 (C4), and 10 (C10) hours after administration on postoperative days 3, 7, and 21. We assessed area under the concentration time curve (AUC) (hour · μg/mL), normalized serum concentration (NSC) at C0 [concentration (μg/mL)/dose (mg/kg body weight)], and estimated glomerular filtration rate (eGFR). The mizoribine concentration showed increases at C3 and C4 followed by a decrease at C10 on all days. AUC was 4.3, 5.9, and 8.3 in the 200-mg/d dose group on days 3, 7, and 21, respectively. NSC at C0 increased for 3 weeks after LDLT. There was a significant correlation between the NSC at C0 and eGFR on day 21, but not on days 3 and 7. There were no correlations between the NSC at C0 and either aspartate aminotransferase, total bilirubin, albumin, trough cyclosporine, or trough tacrolimus on any day. The pharmacokinetics of mizoribine in the acute phase after LDLT seems to be affected by postoperative day and renal function.
UR - http://www.scopus.com/inward/record.url?scp=84861901230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861901230&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2012.01.139
DO - 10.1016/j.transproceed.2012.01.139
M3 - Article
C2 - 22664010
AN - SCOPUS:84861901230
VL - 44
SP - 1329
EP - 1335
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 5
ER -